| Literature DB >> 35566388 |
Juman Mohammed Rasmi Alamil1, Keshav Raj Paudel2, Yinghan Chan3, Dikaia Xenaki4, Jithendra Panneerselvam5, Sachin Kumar Singh6,7, Monica Gulati6,7, Niraj Kumar Jha8, Deepak Kumar9, Parteek Prasher10, Gaurav Gupta11,12,13, Raniya Malik14, Brian George Oliver4,15, Philip Michael Hansbro2, Kamal Dua4,7,16, Dinesh Kumar Chellappan17.
Abstract
The inflammatory response is a central aspect of the human immune system that acts as a defense mechanism to protect the body against infections and injuries. A dysregulated inflammatory response is a major health concern, as it can disrupt homeostasis and lead to a plethora of chronic inflammatory conditions. These chronic inflammatory diseases are one of the major causes of morbidity and mortality worldwide and the need for them to be managed in the long term has become a crucial task to alleviate symptoms and improve patients' overall quality of life. Although various synthetic anti-inflammatory agents have been developed to date, these medications are associated with several adverse effects that have led to poor therapeutic outcomes. The hunt for novel alternatives to modulate underlying chronic inflammatory processes has unveiled nature to be a plentiful source. One such example is agarwood, which is a valuable resinous wood from the trees of Aquilaria spp. Agarwood has been widely utilized for medicinal purposes since ancient times due to its ability to relieve pain, asthmatic symptoms, and arrest vomiting. In terms of inflammation, the major constituent of agarwood, agarwood oil, has been shown to possess multiple bioactive compounds that can regulate molecular mechanisms of chronic inflammation, thereby producing a multitude of pharmacological functions for treating various inflammatory disorders. As such, agarwood oil presents great potential to be developed as a novel anti-inflammatory therapeutic to overcome the drawbacks of existing therapies and improve treatment outcomes. In this review, we have summarized the current literature on agarwood and its bioactive components and have highlighted the potential roles of agarwood oil in treating various chronic inflammatory diseases.Entities:
Keywords: agarwood; agarwood oil; anti-inflammatory; herbs; inflammation; therapeutics
Mesh:
Substances:
Year: 2022 PMID: 35566388 PMCID: PMC9104417 DOI: 10.3390/molecules27093038
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1Cellular events during an acute inflammatory response.
Summary of the inflammatory processes in different body organs.
| Place of | Causes | Mediators | Consequences | Reference |
|---|---|---|---|---|
| Intestine | Infections | Campylobacter and Salmonella | Inflammatory bowel disease (IBD) | [ |
| Food | Food with fatty acid compounds | Crohn’s disease | [ | |
| Dysbiosis | Gut microbiome | Acute gastroenteritis, IBD | [ | |
| Environmental factors | Smoking, nutrition, climate, pollution | IBD | [ | |
| Stomach lining | Infections |
| Ulcerative colitis | [ |
| NSAIDs | Reduced prostaglandin production due to inhibition of COX1 and COX2 | Colitis, IBD | [ | |
| Psychological stress, | Increased acid load, effects of hypothalamic-pituitary-adrenal axis activation on healing, altered blood flow, or cytokine-mediated impairment of mucosal defenses | Peptic ulcer | [ | |
| Physical stress like brain injury | Traumatic head injury can cause increased intracranial pressure and lead to overstimulation of the vagus nerve and increased secretion of gastric acid. | Cushing’s ulcer. | [ | |
| Joint | Hyperuricemia | Increase uric acid deposition in joint | Gout (Joint inflammation) | [ |
| Genetics | HLA-DRB1 alleles: HLA-DRB1*04, HLA-DRB1*01, and HLA-DRB1*10. | Rheumatoid arthritis | [ | |
| Mutations in genes encoding types II, IV, V, and VI collagens | ||||
| Environmental/Diet factors | Smoking and alcohol intake | Rheumatoid arthritis | [ | |
| Autoimmune | Anti-citrullinated protein/peptide antibodies | Rheumatoid arthritis | [ | |
| Brain | Infections | Herpes simplex | Encephalitis | [ |
| Human immune deficiency virus | ||||
| Autoimmune disorder | Anti-N-methyl-D-aspartate receptor (anti-NMDA) encephalitis | Autoimmune encephalitis | [ | |
| Autoimmune Meningitis | ||||
| Ischemia | Blocking or narrowing of artery leading to brain | Vascular brain injury, Stroke | [ | |
| Lung | Cigarette smoke | Components of cigarette smoke that mediate oxidative stress and inflammatory | Airway inflammation, COPD | [ |
| Allergen | Increase inflammatory cytokines by allergens such as Ovalbumin | Airway inflammation, allergic asthma | [ | |
| Air pollution | Particulate matter (PM) from traffic, industries, and ozone | Airway disease | [ | |
| Infections | Influenza-induced exacerbation | Airway inflammation, Chronic lung disease | [ | |
| Dysbiosis | Lung microbiome | Airway inflammation, Chronic lung disease | [ | |
| Bushfire/Wildfire smoke | Complex mix of inspirable particles, volatile organics, aldehydes, carbon monoxide, and particulate | Airway inflammation, Chronic lung disease | [ |
Various species of Aquilaria and their distribution.
| Species | Agarwood-Producing | Distribution | Reference |
|---|---|---|---|
|
| Yes | Thailand, Indonesia, Papua New Guinea, Philippines | [ |
|
| Yes | Philippines | [ |
|
| Yes | Cambodia, Laos, Thailand | [ |
|
| Yes | Vietnam | [ |
|
| Yes | Malaysia, Indonesia, Brunei | [ |
|
| Yes | Malaysia, Philippines | [ |
|
| No | Philippines | [ |
|
| Yes | Thailand, Vietnam, Laos, India, Cambodia, Malaysia | [ |
|
| Yes | Indonesia, Philippines | [ |
|
| Yes | Indonesia, Singapore, Malaysia, China, Philippines | [ |
|
| Yes | China | [ |
|
| Yes | Indonesia, Malaysia, Thailand, Singapore | [ |
|
| Yes | Bangladesh, India | [ |
|
| Yes | Bhutan, Thailand, Malaysia, India, Vietnam, Bangladesh, Indonesia, Iran, Myanmar, Singapore, Philippines | [ |
|
| Yes | Indonesia, Malaysia, Singapore | [ |
|
| No | Indonesia | [ |
|
| No | Philippines | [ |
|
| No | Bhutan, Laos, Thailand, Myanmar | [ |
|
| Yes | Malaysia | [ |
|
| No | Thailand, Vietnam | [ |
|
| Yes | China | [ |
|
| Yes | Malaysia, Thailand | [ |
|
| No | Philippines | [ |
|
| No | China | [ |
Summary of various agarwood-inducing methods.
| Type | Examples | Concept | Advantage | Disadvantage | Reference |
|---|---|---|---|---|---|
| Natural | Thunder strike | Wounds are created which then triggers the activation of the tree’s defense system, thereby producing resin | High-quality agarwood | Extremely low agarwood yield | [ |
| Animal grazing | |||||
| Pest and disease | |||||
| Broken branches | |||||
| Microbial invasion | |||||
| Artificial conventional | Physical wounding | Mimics natural factors by creating physical wounds on the trees which will then trigger the formation of agarwood via tree’s defense mechanism | Cost-effective | Laborious | [ |
| Cauterizing | |||||
| Nailing | |||||
| Holing | |||||
| Bark removal | |||||
| Trunk pruning | |||||
| Burning-chisel-drilling | |||||
| Artificial biological | Fungal strains such as | Introduction of microbial cultures into | Eco-friendly and safe for handling | Long incubation time is required to produce high-quality agarwood | [ |
| Time-consuming holing process for inoculating microbial cultures | |||||
| Inconsistency in agarwood quality depending on fungal species and site of inoculation | |||||
| Artificial chemical | Chemicals or signaling molecules such as ferric chloride, ferrous chloride, salicylic acid, sodium methyl bisulfide, hydrogen peroxide, formic acid, cellobiose, and methyl jasmonate | Direct induction of tree’s defense mechanism for the secretion of resin | Easy to apply with rapid action | An appropriate amount must be applied as an excess could kill the tree | [ |
| Minimize the time required for holing processes | |||||
| Suitable for large scale plantations | |||||
| Ease of quality control | |||||
| High-quality agarwood with high and consistent yields | |||||
| Agarwood formation can be induced in the whole tree |
Summary of studies on compounds extracted from agarwood with proven anti-inflammatory action.
| Compound | Study Model | Anti-Inflammatory Outcomes | Reference | |
|---|---|---|---|---|
| Inflammatory Pathways | Key Findings | |||
| 2-(2-phenylethyl) chromone | In vitro study on RAW 264.7 cells. | Inhibit the activation of MAPK and STAT pathways. | Inhibit the production of NO, TNF-α, IL-6, IL-1β, PGE2. | [ |
| In vitro study on RAW 264.7 cells. | Inhibit NF-κB activation. | Inhibit the production of NO. | [ | |
| In vitro study on RAW 264.7 cells. | Not specified. | Inhibit the production of NO. | [ | |
| Sesquiterpenoids | In vitro study on RAW 264.7 cells. | Not specified. | Inhibit the production of NO. | [ |
| In vitro study on RAW 264.7 cells. | Not specified. | Inhibit the production of NO. | [ | |
| In vitro study on RAW 264.7 cells. | Not specified. | Inhibit the production of NO. | [ | |
| Others: β-caryophyllene | In vivo study on rats with paw edema induced with carrageenan. | Not specified. | Reduced edema in rat paws. | [ |
| α-humulene | Ovalbumin induced mice model of allergic asthma | inhibition of the activation of p65 NF-kB and c-Jun AP-1 | reduction of eosinophils in the bronchoalveolar lavage fluid as well as inflammatory mediators such as IFN-γ, IL-5, CCL11, and LTB4 levels. | [ |
Figure 2Possible mechanisms by which agarwood oil could inhibit chronic inflammatory processes.
Summary of studies proving the anti-inflammatory properties of agarwood oil.
| Study Model(s) | Concentration | Study Duration | Anti-Inflammatory Outcomes | Reference | |
|---|---|---|---|---|---|
| Inflammatory | Key Findings | ||||
| In vivo and in vitro study on carrageenan-induced rat paw edema and HRBC stabilization method | In vivo: 50 and 100 mg/kg | In vivo: 4 h | Inhibition of the cyclooxygenase (COX) inflammatory pathway | Strong inhibition of rat paw edema. | [ |
| In vitro: 100, 250, and 500 mcg/mL | Inhibition of cell membrane lysis induced by hypotonicity. | ||||
| In vivo study on carrageenan-induced rat paw edema and xylene-induced ear edema in mice | Mice: 60 to 960 mg/kg | Not specified | Inhibit the expression p-STAT3 gene. | Reduce the production of IL-1β and IL-6. | [ |
| Rats: 680 mg/kg | |||||
| In vitro study on RAW 264.7 cells | Not specified | Not specified | Not specified. | Inhibit the release of TNF-α and IL-1α. | [ |
| In vivo study on mice induced with ear inflammation and in silico studies: ADME and QSAR | In vivo: 20 uL/ear for 3 times | 24 h | Not specified. | Reduce inflammation in mice ears. | [ |
| Inhibit the release of IL-1β, IL-6, and TNF-α. | |||||
| ADME and QSAR results corresponding to anti-inflammatory activity. | |||||
| In vivo study on rats with paw edema induced with carrageenan and with granuloma induced with cotton pellets | 50, 100 and 200 mg/kg | Carrageenan-induced paw edema: 3 h | Not specified. | Inhibit the activity of prostaglandins (PGE2 and PGI2). | [ |
| Reduced edema in rat paws. | |||||
| Smaller size granuloma compared to control group. | |||||
| In vitro study on hPBMCs | 0.5, 1.0, 1.5, 2.0, 2.5, and 3.0 mg/mL | 24 h | Inhibit the p38 MAPK activation. | Inhibit the production of TNF-α. | [ |
| In vivo study on mice with intestinal injury induced by 5-flurouracil | 200, 400, and 800 mg/kg | 7 days | Inhibiting the oxidative stress. | Less symptoms of intestinal inflammation. | [ |
| Inhibiting the expression of inflammatory mediators. | Less tissue inflammation observed on histopathology and improved recovery. | ||||
| Inhibiting the NF-κB pathway. | Decreased levels of COX-2 and TNF-α inflammatory mediators in the intestinal cells. | ||||
| In vivo study on mice with intestinal injury induced by 5-flurouracil | 0.71, 1.42 and 2.84 g/kg | 14 days | Inhibiting oxidative stress. | Improved body weight and intestinal propulsion. | [ |
| Less mucosal injury. | |||||
| Decreased levels of NO and increased glutathione and superoxide dismutase activity. | |||||
| Decreased the levels of IL-17, IL-33, and increased IL-10. | |||||
| Inhibiting the NF-κB pathway | |||||
| In vivo study on mice with gastric ulcers induced by ethanol | 0.71, 1.42 and 2.84 g/kg | 7 days | Inhibiting oxidative stress. | Protective effect against gastric ulcer and lesser degree of inflammation. | [ |
| Decreased levels of IL-1β, IL-6, and increased level of IL-10. | |||||
| Inhibition of the NF-κB and p38 MAPK pathways. | |||||
| In vitro bovine serum protein (BSA) denaturation method and in vivo Freund’s-adjuvant-induced arthritic rat model | In vivo: 125 and 250 mg/kg | In vivo: 21 days | Inhibition of protein denaturation. | Reduced paw edema by gross observation and radiography. | [ |
| In vitro: 100, 250 and 500 mcg/mL | Inhibition of inflammatory mediators. | Improved hematological parameters. | |||
| In vivo study on methanol induced inflammation in livers and brains of rats | 100 mg/kg | 35 days | Inhibit oxidative stress and apoptosis. | Inhibit the release of NO, MDA, ACHE, COX-2, LOX, TNF-α, Caspase-3, MAO, and DNAF neurotransmitters and pro-inflammatory mediators. | [ |
| In vivo study on stress-induced anxiety and depression in rats | 10, 20 and 40 mg/kg | 10 days | Decreases the levels of IL-1α, IL-1β, and IL-6 in serum. | Antidepressant effect. | [ |
| Anxiolytic effect. | |||||
| Decreased levels of ACTH and CORT serum. | |||||
| In vivo study on rats with stress-induced with epinephrine | 100 mg/kg | 21 days | Inhibition of cortisol production. | Reduced levels of lipid peroxidation, NO, TNF-α, IL-1β, cortisol, COX-2, LOX, AST, ALT, and lipids. | [ |